AIMS: Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of human cancers. The aim of this study was to evaluate RKIP expression and to determine its association with metastasis and prognostic significance in pancreatic cancer patients. METHODS: Immunohistochemical staining for RKIP was performed on 63 cases of pancreatic ductal adenocarcinoma (PDAC). We investigated whether RKIP expression correlated with clinicopathological parameters and patient outcomes. RESULTS: The islet cells, acinar cells and ductal epithelial cells of normal pancreas consistently showed strong RKIP immunoreactivity. In contrast, in PDAC, RKIP was lost in 57.1% (37/63) of cases. Loss of RKIP expression was significantly associated with the presence of nodal (p=0.001) and distant (p=0.010) metastases and a higher stage group (p=0.012). Univariate analysis for distant metastasis-free survival (DMFS) showed that the median DMFS of RKIP negative PDAC patients (10 months) was significantly shorter than that of RKIP positive PDAC patients (17 months; p=0.009). Multivariate analysis also revealed that loss of RKIP expression was an independent predictor of worse DMFS in PDAC patients (p=0.015). CONCLUSIONS: Our results strongly suggest that RKIP is a metastasis suppressor in PDAC.
AIMS: Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of humancancers. The aim of this study was to evaluate RKIP expression and to determine its association with metastasis and prognostic significance in pancreatic cancerpatients. METHODS: Immunohistochemical staining for RKIP was performed on 63 cases of pancreatic ductal adenocarcinoma (PDAC). We investigated whether RKIP expression correlated with clinicopathological parameters and patient outcomes. RESULTS: The islet cells, acinar cells and ductal epithelial cells of normal pancreas consistently showed strong RKIP immunoreactivity. In contrast, in PDAC, RKIP was lost in 57.1% (37/63) of cases. Loss of RKIP expression was significantly associated with the presence of nodal (p=0.001) and distant (p=0.010) metastases and a higher stage group (p=0.012). Univariate analysis for distant metastasis-free survival (DMFS) showed that the median DMFS of RKIP negative PDAC patients (10 months) was significantly shorter than that of RKIP positive PDAC patients (17 months; p=0.009). Multivariate analysis also revealed that loss of RKIP expression was an independent predictor of worse DMFS in PDAC patients (p=0.015). CONCLUSIONS: Our results strongly suggest that RKIP is a metastasis suppressor in PDAC.
Authors: F N Pardo; J Altirriba; M Pradas-Juni; A García; U Ahlgren; A Barberà; J C Slebe; A J Yáñez; R Gomis; R Gasa Journal: Diabetologia Date: 2012-08-29 Impact factor: 10.122
Authors: José G Treviño; Monika Verma; Sandeep Singh; Smitha Pillai; Dongyu Zhang; Daniele Pernazza; Said M Sebti; Nicholas J Lawrence; Barbara A Centeno; Srikumar P Chellappan Journal: Mol Cancer Ther Date: 2013-10-09 Impact factor: 6.261
Authors: Olga Martinho; Filipe Pinto; Sara Granja; Vera Miranda-Gonçalves; Marise A R Moreira; Luis F J Ribeiro; Celso di Loreto; Marsha R Rosner; Adhemar Longatto-Filho; Rui Manuel Reis Journal: PLoS One Date: 2013-03-19 Impact factor: 3.240